Anti-HBV neonatal immunization with recombinant vaccine. Part II. Molecular basis of the impaired alloreactivity

Martinetti, Miryam; Cuccia, M.; Daielli, C.; Ambroselli, F.; Gatti, Carlo; Pizzochero, C.; Belloni, C; Orsolini, P; Salvaneschi, L.

doi:10.1016/0264-410x(94)00044-n

Cited by 24 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, in a very recent paper, Leonardi et al comparing a group of patient afected by diabetes mellitus type 1 (DMT1) and CD and a group afected by DMT1 without CD (both groups had similar HLA haplotype) found a higher nonsigniicant percentage of nonresponders in DMT1/CD group than in DMT1 (53.3% versus 38.2%); comparing the DMT1/CD group with CD group, the authors found a similar percentage (53.3% versus 50%) of nonresponders, and this result indirectly conirmed that gluten can favor a further decrease of eicacy to HBV vaccine, beyond the HLA system [29]. to the recombinant HBV vaccine [9,[30][31][32]. HLA is believed to contribute signiicantly to the genetic susceptibility immune response variations to the vaccine [33].…”

Section: Responses To Vaccinations In Celiac Childrensupporting

confidence: 67%

Celiac Disease and HBV Vaccination

Anania¹,

Olivero²,

Olivero³

et al. 2017

Celiac Disease and Non-Celiac Gluten Sensitivity

View full text Add to dashboard Cite

Celiac disease (CD) is an immune-mediated systemic disorder elicited by gluten and related prolamins in genetically susceptible individuals, characterized by the presence of a variable combination of gluten-dependent clinical manifestations, CD-speciic antibodies, HLA-DQ2 and HLA-DQ8 haplotypes, and enteropathy. Hepatitis B virus (HBV) infection is an important global public health problem that can cause chronic liver disease, and it is associated to a high risk of death from cirrhosis and hepatocellular carcinoma. Since 1982, a safe and efective HBV vaccine has been available, and recommendation for HBV vaccination has been extended to all infants to achieve protection against HBV infection. HBV vaccination is highly efective in eliciting a sustained immune response in immune-competent individuals. However, research papers have suggested that celiac patients may have low rate of protective antibodies after HBV vaccination. The failure of CD subjects to respond to HBV vaccination has great importance for public health policies as the nonresponders could be regarded as a reservoir for HBV. The aim of our work is to revise and to discuss the scarce literature on this ield in order to provide clinical practice guidelines to establish the best surveillance program of response to HBV vaccine in CD pediatric patient.

show abstract

Section: Responses To Vaccinations In Celiac Childrensupporting

confidence: 67%

Celiac Disease and HBV Vaccination

Anania¹,

Olivero²,

Olivero³

et al. 2017

Celiac Disease and Non-Celiac Gluten Sensitivity

View full text Add to dashboard Cite

show abstract

“…40 Also of relevance is the previously reported association of DRB1*1104 with a favorable response to hepatitis B surface antigen vaccination. 41 Studies from other investigators support the role of HLA DRB variation in modulating hepatitis C severity. A protective role has been reported for HLA DR5 and DR6 and for DR6 subtypes HLA DRB1*1301-03 in a Northern European population, 15 and the presence of HLA DR5 has been inversely associated with cirrhosis in Italy.…”

Section: Discussionmentioning

confidence: 95%

Human Leukocyte Antigen Class Ii and Iii Alleles and Severity of Hepatitis C Virus-Related Chronic Liver Disease

et al. 1999

View full text Add to dashboard Cite

Hepatitis C outcome is likely related both to viral factors and host's immune responses. We correlated the severity of liver disease with human leukocyte antigen (HLA) genes (C4A, C4B, TNFA, TNFB, DRB1, DRB3, DRB4, DRB5, DQA1, DQB1, TAP1, and TAP2) in three groups of subjects: 99 patients with chronic hepatitis, 41 asymptomatic carriers, and 179 uninfected controls. Patients with grade/stage 3 to 4 hepatitis significantly differentiated for their low frequency of alleles TNFB*1, DRB1*1104, and DRB3*03, which had a protective role, and high frequency of allele DRB1*1001, which was associated with disease severity. HLA-DRB*11 subtypes were differentially distributed: DRB1*1104 was most frequent in carriers, whereas DRB1*1101 was more frequent in patients. The TAP1C,2A haplotype was also underrepresented in patients with respect to controls. Finally, a decrease of heterozygous subjects was observed in patients with respect to carriers at the DQB1 locus. Multivariate analysis by correspondence analysis and multiple logistic regression indicated that age, sex, and hepatitis C virus (HCV) type were the strongest risk factors; however, some immunogenetic variables (TNFB*1, DRB1*1104, and DRB3*03) showed an independent contribution, especially in comparing patients with extreme manifestations of disease. The involvement of different genes in various HLA subregions suggests that anti-HCV responses are modulated by a complex gene interplay rather than by single alleles. (HEPATOLOGY 1999;29: 1272-1279.)Hepatitis C virus (HCV) is the major cause of chronic liver disease in Italy and accounts for over 70% of cirrhosis and hepatocellular carcinomas. 1 HCV infection results in high rates of chronicization and in a broad spectrum of liver lesions, ranging from mild inflammation to liver failure.Mechanisms underlying viral persistence and liver damage in chronic HCV infection are marginally known, a complex interplay of viral and immunologic factors being likely involved. Immunomediated mechanisms are believed to play a major role, 2-4 as is suggested by the lack of evidence for a cytopathic effect of the virus, 2 the severe course of infection in immunosuppressed patients, 5 the frequent occurrence of immunologic disorders, 6 and the cytokine-mediated expression of immunoregulatory molecules in the infected liver. 7

show abstract

“…One mechanism identified with variations in humoral (150,(174)(175)(176)(177)(178)(179)(180)(181)(182)(183)(184)(185)(186)(187)(188)(189)(190) and cellular (145,150,186,191) vaccine responses is polymorphism in major histocompatibility complex (MHC) genes (summarized in Table 3). Further genetic factors are polymorphisms in pattern recognition receptors (PRRs), such as Toll-like receptor (TLR) or RIG-like receptor (RLR) genes (192)(193)(194)(195) (Table 3).…”

Section: Lower Vaccine Responses In Neonates and Young Infantsmentioning

confidence: 99%

Factors That Influence the Immune Response to Vaccination

2019

View full text Add to dashboard Cite

SUMMARYThere is substantial variation between individuals in the immune response to vaccination. In this review, we provide an overview of the plethora of studies that have investigated factors that influence humoral and cellular vaccine responses in humans. These include intrinsic host factors (such as age, sex, genetics, and comorbidities), perinatal factors (such as gestational age, birth weight, feeding method, and maternal factors), and extrinsic factors (such as preexisting immunity, microbiota, infections, and antibiotics). Further, environmental factors (such as geographic location, season, family size, and toxins), behavioral factors (such as smoking, alcohol consumption, exercise, and sleep), and nutritional factors (such as body mass index, micronutrients, and enteropathy) also influence how individuals respond to vaccines. Moreover, vaccine factors (such as vaccine type, product, adjuvant, and dose) and administration factors (schedule, site, route, time of vaccination, and coadministered vaccines and other drugs) are also important. An understanding of all these factors and their impacts in the design of vaccine studies and decisions on vaccination schedules offers ways to improve vaccine immunogenicity and efficacy.

show abstract

Anti-HBV neonatal immunization with recombinant vaccine. Part II. Molecular basis of the impaired alloreactivity

Cited by 24 publications

References 22 publications

Celiac Disease and HBV Vaccination

Celiac Disease and HBV Vaccination

Human Leukocyte Antigen Class Ii and Iii Alleles and Severity of Hepatitis C Virus-Related Chronic Liver Disease

Factors That Influence the Immune Response to Vaccination

Contact Info

Product

Resources

About